Program
Lutetium Lu 177-labeled FAP-targeting Ligand IM-3050
Its studies are led by Immunome.
Furthest: phase 1, since Mar 18, 20261 company-led study, 1 open or runningNext primary completion: Dec 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immunome | 11 open or running | phase 1since Mar 18, 2026 | Mar 18, 2026 | Dec 2029phase 1 · NCT07505771 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 18, 2026First study: phase 1 study in Solid MalignanciesFirst studyNCT07505771 · 105 planned · United States
Ahead
- Dec 2029Primary completion: phase 1 study in Solid MalignanciesNCT07505771
TargetBeta
FAP →read by rule
“A radioconjugate composed of IM-3050, a small molecule fibroblast activation protein (FAP)-targeting ligand with an albumin-binding domain, a linker, and a chelator, ”NCIt, by rule
Other programs on FAP
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lutetium-177 | Novartis | phase 3 | 24 |
| Gallium-68 | Philogen | phase 3 | 17 |
| Fluorine F 18 FAPI-74rule | sofie | phase 3 | 3 |
| Fluorine F 18 FPyQCPrule | Bracco | phase 2 | 1 |
| HRS-6768 | Jiangsu HengRui Medicine | phase 2 | 1 |
| Anti-FAP Antibody-drug Conjugate OMTX705rule | oncomatryx-biopharma-s-l | phase 1 | 2 |
| Gallium Ga 68 NNS309 | Novartis | phase 1 | 2 |
| Actinium Ac 225 RTX-2358rule | ratio-therapeutics-inc | phase 1 | 1 |
| Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713rule | Eli Lilly | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07505771Solid Malignancies · United States | 1 | Recruiting | Dec 2029 | 105 |
How it is read
Names in the registry
- “177Lu-IM-3050”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.